Microbiología y parasitología
Especialidad
Hospital del Mar
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital del Mar (34)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
2023
-
Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial
Nature Medicine, Vol. 29, Núm. 10, pp. 2518-2525
-
Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort
International Journal of Infectious Diseases, Vol. 137, pp. 134-143
2022
-
Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients
Orphanet Journal of Rare Diseases, Vol. 17, Núm. 1
-
Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria
Open Forum Infectious Diseases, Vol. 9, Núm. 9
2021
-
Correction to: The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients (Critical Care, (2021), 25, 1, (331), 10.1186/s13054-021-03727-x)
Critical Care
-
Executive summary of the Consensus Document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and of the Spanish Association of Surgeons (AEC) in antibiotic prophylaxis in surgery
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 1, pp. 29-40
-
Executive summary of the Consensus Document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and of the Spanish Association of Surgeons (AEC) in antibiotic prophylaxis in surgery
Cirugia Espanola, Vol. 99, Núm. 1, pp. 11-26
-
Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: Study protocol for the SAFO trial
BMJ Open, Vol. 11, Núm. 8
-
The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients
Critical Care, Vol. 25, Núm. 1
2019
-
Discrepancy in the genotypic versus phenotypic testing for resistance to rifampicin in Mycobacterium tuberculosis. A case report
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 212-213
2018
-
Erratum for del Barrio-Tofiño et al., "Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain"
Antimicrobial agents and chemotherapy
2017
-
Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia
Clinical Microbiology and Infection, Vol. 23, Núm. 1, pp. 49.e1-49.e8
-
Genomics and susceptibility profiles of extensively drug-resistant pseudomonas aeruginosa isolates from Spain
Antimicrobial Agents and Chemotherapy, Vol. 61, Núm. 11
2016
-
Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort
Clinical Microbiology and Infection, Vol. 22, Núm. 8, pp. 733.e1-733.e8
-
High Body Mass Index as a Risk Factor for Hospitalization Due to Influenza: A Case-Control Study
Archivos de Bronconeumologia, Vol. 52, Núm. 6, pp. 299-307
-
Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial
International Journal of Antimicrobial Agents, Vol. 48, Núm. 3, pp. 310-316
2015
-
A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains
Clinical Microbiology and Infection, Vol. 21, Núm. 7, pp. 684.e1-684.e9
-
Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance
Journal of Infection, Vol. 71, Núm. 3, pp. 385-394
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792